Categories: News

Edison Issues Report on discoverIE Group (DSCV)

London, United Kingdom–(Newsfile Corp. – December 15, 2025) – Edison issues report on discoverIE Group (LSE: DSCV).

discoverIE reported solid H126 results, with adjusted EPS growth of 6% on reported revenue growth of 2.5%. Organic revenue growth has resumed at the group level and in three out of the four operating units, and two acquisitions have just been announced. Having managed the group to grow earnings and optimise cash during an 18-month period of organic revenue reduction due to industry-wide customer destocking, the company is well-positioned to benefit as demand recovers, we believe. We see the opportunity for the wide discount to peers to narrow now that the group is back on a top-line growth trajectory.

Click here to read the full report.

All reports published by Edison are available to download free of charge from its website www.edisongroup.com

Edison is authorised and regulated by the Financial Conduct Authority.

Edison is not an adviser or broker-dealer and does not provide investment advice. Edison’s reports are not solicitations to buy or sell any securities.

For more information, please contact Edison:

enquiries@edisongroup.com

+44 (0)20 3077 5700

Connect with Edison on:

LinkedIn www.linkedin.com/company/edison-group-/
X www.x.com/edison_inv_res
YouTube www.youtube.com/edisonitv

To view the source version of this press release, please visit https://www.newsfilecorp.com/release/278038

Staff

Recent Posts

Understanding When to Use Fillers or Neurotoxins According to Dr. Ran Rubinstein

Dr. Ran Rubinstein discusses how individualized treatment planning determines when fillers, neurotoxins, or collagen-stimulating injectables…

2 hours ago

China SXT Pharmaceuticals, Inc. Announces Share Consolidation

TAIZHOU, China, Jan. 30, 2026 (GLOBE NEWSWIRE) -- China SXT Pharmaceutics, Inc. (Nasdaq: SXTC) (the…

2 hours ago

Amplia Therapeutics – Quarterly Activities and Cash Flow Reports – December 2025

Melbourne, Australia, Jan. 30, 2026 (GLOBE NEWSWIRE) -- Key Highlights from the Quarter ACCENT Trial…

2 hours ago

ALX Oncology Announces Pricing of Underwritten Offering

SOUTH SAN FRANCISCO, Calif., Jan. 30, 2026 (GLOBE NEWSWIRE) -- ALX Oncology Holdings Inc. (“ALX…

2 hours ago

Ultragenyx Resubmits Biologics License Application for UX111 AAV Gene Therapy to Treat Sanfilippo Syndrome Type A (MPS IIIA) to U.S. FDA

Company expects up to six-month review period per FDA guidelines  New longer-term clinical data demonstrating…

2 hours ago